Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Diagnosis and Treatment, Clinical Research, Research, Novel Treatments, Medical Community Our MBClife Diagnosis and Treatment, Clinical Research, Research, Novel Treatments, Medical Community Our MBClife

Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?

Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.

Read More
ER Progression and Resistance: Causes, Consequences, and Hope
Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife Novel Treatments, Obstacles to Better Outcomes, Medical Community, Entities of Cancer, Difficult to Treat, Clinical Research, Precision Oncology, MBC Imaging and Profiling, Translational Research, Basic Science, Diagnosis and Treatment, Patient Reported Outcomes and Out of the Box Treatment Options Our MBClife

ER Progression and Resistance: Causes, Consequences, and Hope

Endocrine therapy is an effective way to treat hormone-sensitive breast cancers, but de novo and acquired resistance to this treatment remains a major challenge. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance.

Read More